These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Epstein M Am J Med; 2006 Nov; 119(11):912-9. PubMed ID: 17071154 [TBL] [Abstract][Full Text] [Related]
6. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease. Bravo EL Curr Hypertens Rep; 2003 Apr; 5(2):122-5. PubMed ID: 12642011 [TBL] [Abstract][Full Text] [Related]
7. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985 [TBL] [Abstract][Full Text] [Related]
8. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage. Waanders F; de Vries LV; van Goor H; Hillebrands JL; Laverman GD; Bakker SJ; Navis G Curr Vasc Pharmacol; 2011 Sep; 9(5):594-605. PubMed ID: 21529330 [TBL] [Abstract][Full Text] [Related]
9. [Mineralocorticoid receptor antagonists in chronic kidney disease - pros and cons]. Jędras M; Filipowicz E Wiad Lek; 2017; 70(6 pt 2):1205-1208. PubMed ID: 29533915 [TBL] [Abstract][Full Text] [Related]
10. Aldosterone as a determinant of cardiovascular and renal dysfunction. Epstein M J R Soc Med; 2001 Aug; 94(8):378-83. PubMed ID: 11461980 [No Abstract] [Full Text] [Related]
11. Hyperkalaemia in the age of aldosterone antagonism. Chapagain A; Ashman N QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454 [TBL] [Abstract][Full Text] [Related]
12. Vascular actions of aldosterone. Briet M; Schiffrin EL J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373 [TBL] [Abstract][Full Text] [Related]
13. [Old and new drugs to block aldosterone and ameliorate cardiovascular disease]. Fiebeler A; Luft FC Dtsch Med Wochenschr; 2004 Nov; 129(46):2491-6. PubMed ID: 15536584 [No Abstract] [Full Text] [Related]
14. Aldosterone: effects on the kidney and cardiovascular system. Briet M; Schiffrin EL Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356 [TBL] [Abstract][Full Text] [Related]
15. Hyperkalemia and inhibitors of the renin-angiotensin-aldosterone system. Segal A N Engl J Med; 2004 Dec; 351(23):2450-1; author reply 2450-1. PubMed ID: 15575066 [No Abstract] [Full Text] [Related]
17. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Bomback AS; Toto R Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925 [TBL] [Abstract][Full Text] [Related]
18. Aldosterone: cardiovascular assault. Struthers AD Am Heart J; 2002 Nov; 144(5 Suppl):S2-7. PubMed ID: 12422134 [TBL] [Abstract][Full Text] [Related]
19. [Role of RAAS inhibitors for the treatment of heart failure]. Murohara T Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806 [TBL] [Abstract][Full Text] [Related]
20. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. Weinberg MS; Weinberg AJ; Zappe DH J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029 [No Abstract] [Full Text] [Related] [Next] [New Search]